News

Vitrolife in IVF technology deal
Enlarge image

BusinessHungarySweden

Vitrolife in IVF technology deal

02.07.2012 - Cell cultivation company Vitrolife announced it will acquire Hungarian Cryo Management Ltd, a specialist in time-lapse embryo monitoring for IVF.

Gothenburg – The purchase sum is €5m, and could be increased to €9m upon the fulfilment of defined objectives primarily related to sales during the period 2013 to 2015. Through the acquisition, Vitrolife gains access to a product portfolio in the form of time-lapse products for IVF and increased knowledge within IVF technology and embryo development.

The fixed purchase sum is financed by a corporate acquisition loan of €3m and by payment of €2m in newly issued shares or cash. If payment is in shares, this is planned to be carried out after distribution of the subsidiary Xvivo Perfusion AB.  Vitrolife, headquartered in Gothenburg in Sweden, anticipates that the acquisition will have a marginally negative effect on earnings per share for 2012 due to increased marketing activities and transaction expenses but that the business will make a positive contribution as from 2013.  Cryo Management Ltd and its subsidiary Cryo Innovation Ltd are located in Budapest, Hungary. The company was formed in 2005, with 20 employees and budgeted sales of approximately €2m for 2012. The company has developed, produced and marketed time-lapse products, primarily for the IVF market. Its Primo Vision time-lapse technology  takes images of the embryos at short intervals during the cultivation process. The pictures are then played back as a film which is analysed by an embryologist. This method avoids, amongst other things, today’s problem that the sensitive embryo is subjected to stress when being evaluated as the embryo must be taken out of the incubator for assessment. The time-lapse technology also enables the entire development of the embryo to be studied, which gives greater opportunities to choose the most optimal embryo and thereby improve the chances of pregnancy.

http://www.european-biotechnology-news.com/news/news/2012-03/vitrolife-in-ivf-technology-deal.html

DiabetesFrance

01.09.2015 Sanofi is partnering up with Google’s life sciences team with an ambitious goal: to change the face of diabetes management.

M&ASwitzerlandFrance

31.08.2015 In order to boost its active cosmetic ingredients business, the Swiss flavour and fragrance giant Givaudan has acquired Volketswil-based Induchem Holding and all its subsidiaries.

BioeconomyEU

26.08.2015 In its second call for proposals, the Bio-Based Industries Joint Undertaking has earmarked €106m for the research and development of useful bio-based products.

OncologyNorway

25.08.2015 Oslo Cancer Cluster is inaugurating its NOK1bn (€107m) Innovation Park. None other than Norwegian prime minister Erna Solberg officially opened the doors to the research park on August 24th.

LicensingUKSwitzerland

21.08.2015 Novartis Pharma AG has secured all remaining rights to antibody hopeful ofatumumab. Seller GlaxoSmithKline is set to receive up to US$1bn (€919m) for the treatment for MS and other autoimmune indications.

LicensingDenmark

18.08.2015 Danish Novo Nordisk is climbing on the antibody therapeutics bandwagon in a US$500m licensing agreement with antibody-specialist Genmab.

M&ASwitzerland

13.08.2015 Roche is stepping up its commitment in the fight against drug resistant “superbugs” with its takeover of US diagnostics play Geneweave, for up to US$425m.

M&AUK

11.08.2015 Biotech bug controllers Oxitec has been bought by US biotech Intrexon Corporation for $160m (€145m). The Oxford University spin-out specialises in environmentally friendly technology to control pests such as mosquitoes, which cause dengue fever and other diseases.

Research and DevelopmentFranceGermany

07.08.2015 In a deal worth more than €300m, Sanofi has partnered up with German drug discovery and development company Evotec in order to develop beta cell-modulating diabetes therapies.

Events

All Events

Current issue

All issues

Product of the week

Products

Stock list

All quotes

TOP

  • 4SC (D)3.54 EUR10.62%
  • DEINOVE (F)7.10 EUR7.25%
  • NANOBIOTIX (F)18.43 EUR5.62%

FLOP

  • BIOTIE THERAPEUTICS (FI)0.20 EUR-9.09%
  • OREXO (S)45.30 SEK-8.67%
  • TIGENIX (B)1.12 EUR-7.44%

TOP

  • KARO BIO (S)40.60 SEK2502.6%
  • BIOTECH PHARMACON (N)17.40 NOK84.5%
  • TRANSGENE (F)4.86 EUR73.6%

FLOP

  • CHRONTECH PHARMA (S)0.01 SEK-50.0%
  • BIONOR PHARMA (N)1.17 NOK-44.0%
  • NEUROVIVE PHARMACEUTICAL AB (S)12.85 SEK-43.4%

TOP

  • KARO BIO (S)40.60 SEK4566.7%
  • ADOCIA (F)85.64 EUR389.7%
  • VERONA PHARMA (UK)4.95 GBP312.5%

FLOP

  • CHRONTECH PHARMA (S)0.01 SEK-85.7%
  • NEUROVIVE PHARMACEUTICAL AB (S)12.85 SEK-80.2%
  • BIOTEST (D)20.00 EUR-77.0%

No liability assumed, Date: 02.09.2015